肯塔基 的 骨髓增生異常症候群 臨床試驗
5 項針對 骨髓增生異常症候群 的研究正在 肯塔基 各地點尋找參與者。
肯塔基 的城市
官方研究文本（英文）
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年10月5日 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年10月5日 · NCT06577441A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月18日 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
招募中1/2 期
22 歲以下 · 所有性別 · 更新於 2026年8月25日 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年8月21日 · NCT06499285資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。